• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Insiders Buying Outlook Therapeutics And 2 Other Stocks

    4/1/24 10:46:37 AM ET
    $CION
    $OTLK
    $RKT
    Finance/Investors Services
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CION alert in real time by email

    Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

    Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

    CION Investment

    • The Trade: CION Investment Corporation (NYSE:CION) Co-Chairman & Co-CEO Mark Gatto acquired a total of 1,150 shares an average price of $11.02. To acquire these shares, it cost around $12,673.
    • What’s Happening: On March 14, CION Invt posted downbeat quarterly earnings
    • What CION Investment Does: CION Investment is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company.

    Outlook Therapeutics

    • The Trade: Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin acquired a total of 1,881 shares at an average price of $11.82. To acquire these shares, it cost around $22,242.
    • What’s Happening: On March 27, BTIG upgraded the stock from Neutral to Buy and announced a $50 price target.
    • What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

    Don’t forget to check out our premarket coverage here

    Rocket Companies

    • The Trade: Rocket Companies, Inc. (NYSE:RKT) Director Matthew Rizik bought a total of 301 shares at an average price of $14.57. To acquire these shares, it cost around $4,386.
    • What’s Happening: On March 18, B of A Securities analyst Mihir Bhatia maintained Rocket Companies with an Underperform and raised the price target from $7 to $8.
    • What Rocket Companies Does: Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit.

     

    Check This Out: How To Earn $500 A Month From Verizon Stock On Heels Of Analyst Upgrade

    Get the next $CION alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CION
    $OTLK
    $RKT

    CompanyDatePrice TargetRatingAnalyst
    Rocket Companies Inc.
    $RKT
    1/12/2026$24.00Neutral
    Analyst
    Rocket Companies Inc.
    $RKT
    12/19/2025$25.00Buy
    Jefferies
    Rocket Companies Inc.
    $RKT
    11/13/2025$25.00Outperform
    Oppenheimer
    Rocket Companies Inc.
    $RKT
    9/10/2025$24.00Neutral → Buy
    BofA Securities
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    Rocket Companies Inc.
    $RKT
    8/19/2025$25.00Buy
    BTIG Research
    Rocket Companies Inc.
    $RKT
    8/14/2025$16.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CION
    $OTLK
    $RKT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    It's a Buyer's Market: America Has 44% More Home Sellers Than Buyers—a Near-Record Gap

    Redfin reports that only five metro areas are seller's markets, most of which are located in the Northeast. The South and West are home to the strongest buyer's markets. There were an estimated 44% more home sellers than buyers in the U.S. housing market in January (or 600,314 more, in numerical terms), according to a new report from Redfin, the real estate brokerage powered by Rocket. That's up from 30% more a year earlier and represents the second largest gap in records dating back to 2013. The largest gap was in December 2025, when sellers outnumbered buyers by 45%. Redfin defines a market with over 10% more sellers than buyers as a buyer's market. By this definition, it has been a b

    2/23/26 8:00:00 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

    Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership advances European commercial expansion strategy, with LYTENAVA™ (bevacizumab gamma) expected to launch in Switzerland in 2027 ISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases and Mediconsult AG, Switzerland's leading full-service partner for ophthalmic professionals, today announced th

    2/19/26 9:00:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Redfin Reports Home Prices Start Year Up Just 1% as Buyer's Market Keeps Growth in Check

    Pending home sales fell to the lowest level since 2023 and existing-home sales dropped the most since 2022 as elevated housing costs curbed homebuyer demand The median U.S. home sale price rose 1.1% year over year in January to $422,921 as the strongest buyer's market in recent history kept a lid on price growth. That's according to a new report from Redfin, the real estate brokerage powered by Rocket. Year-over-year price growth has hovered below 2% for the past 10 months—a far cry from the double-digit gains of the pandemic homebuying frenzy. "Home prices grew so fast for so long that a lot of buyers got shut out of the market, which is now causing price growth to cool," said Redfin

    2/19/26 8:30:00 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    $CION
    $OTLK
    $RKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on Rocket Companies with a new price target

    Analyst resumed coverage of Rocket Companies with a rating of Neutral and set a new price target of $24.00

    1/12/26 8:18:29 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    Jefferies initiated coverage on Rocket Companies with a new price target

    Jefferies initiated coverage of Rocket Companies with a rating of Buy and set a new price target of $25.00

    12/19/25 8:50:47 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    Oppenheimer initiated coverage on Rocket Companies with a new price target

    Oppenheimer initiated coverage of Rocket Companies with a rating of Outperform and set a new price target of $25.00

    11/13/25 9:16:47 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    $CION
    $OTLK
    $RKT
    SEC Filings

    View All

    SEC Form 8-K filed by Outlook Therapeutics Inc.

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    2/18/26 5:01:25 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Outlook Therapeutics Inc.

    10-Q - Outlook Therapeutics, Inc. (0001649989) (Filer)

    2/17/26 5:01:15 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

    2/17/26 8:30:36 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CION
    $OTLK
    $RKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kenyon Lawrence A bought $28,446 worth of shares (5,000 units at $5.69), increasing direct ownership by 529% to 5,946 units (SEC Form 4)

    4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

    9/30/24 4:53:23 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Co-Chairman & Co-CEO Reisner Michael A bought $4,932 worth of shares (400 units at $12.33), increasing direct ownership by 0.91% to 44,560 units (SEC Form 4)

    4 - CION Investment Corp (0001534254) (Issuer)

    8/27/24 12:30:09 PM ET
    $CION
    Finance/Investors Services
    Finance

    CCO & Secretary Roman Stephen bought $5,481 worth of shares (450 units at $12.18), increasing direct ownership by 5% to 10,278 units (SEC Form 4)

    4 - CION Investment Corp (0001534254) (Issuer)

    8/21/24 3:49:40 PM ET
    $CION
    Finance/Investors Services
    Finance

    $CION
    $OTLK
    $RKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rizik Matthew sold $114,430 worth of shares (5,000 units at $22.89), decreasing direct ownership by 0.48% to 1,038,536 units (SEC Form 4)

    4 - Rocket Companies, Inc. (0001805284) (Issuer)

    1/13/26 4:03:39 PM ET
    $RKT
    Finance: Consumer Services
    Finance

    Director Rizik Matthew sold $106,374 worth of shares (5,000 units at $21.27), decreasing direct ownership by 0.48% to 1,043,536 units (SEC Form 4)

    4 - Rocket Companies, Inc. (0001805284) (Issuer)

    1/9/26 4:26:28 PM ET
    $RKT
    Finance: Consumer Services
    Finance

    Director Rizik Matthew sold $105,048 worth of shares (5,000 units at $21.01), decreasing direct ownership by 0.47% to 1,048,536 units (SEC Form 4)

    4 - Rocket Companies, Inc. (0001805284) (Issuer)

    1/7/26 4:03:20 PM ET
    $RKT
    Finance: Consumer Services
    Finance

    $CION
    $OTLK
    $RKT
    Leadership Updates

    Live Leadership Updates

    View All

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bentley Systems Set to Join S&P MidCap 400 and Western Union to Join S&P SmallCap 600

    NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Bentley Systems Inc. (NASD: BSY) will replace Western Union Co. (NYSE:WU) in the S&P MidCap 400, and Western Union will replace Mr. Cooper Group Inc. (NASD: COOP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 6. Rocket Companies Inc. (NYSE:RKT) acquired Mr. Cooper Group in a deal that closed today, October 1. Western Union's market capitalization is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name        Action Company Name Ticker GICS Sector October 6, 2025   S&P MidCap

    10/1/25 6:03:00 PM ET
    $BSY
    $RKT
    $SPGI
    Computer Software: Prepackaged Software
    Technology
    Finance: Consumer Services
    Finance

    Rocket Appoints Viral Nation as Social Media Agency of Record, Replacing Glossy Social Feeds with Real Stories

    TORONTO, Aug. 12, 2025 /PRNewswire/ -- Viral Nation, a global leader in social-first transformation, today announced it has been named the Social Media Agency of Record for Rocket, the Detroit-based fintech platform including mortgage, real estate, title, and personal finance businesses. Rocket will leverage Viral Nation's influencer marketing, social strategy, community management, and social content creation abilities to deliver raw, relatable homeownership stories that break through social media's glossy facade. At a time when nearly 80% of social media users turn to their

    8/12/25 9:00:00 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    $CION
    $OTLK
    $RKT
    Financials

    Live finance-specific insights

    View All

    Rocket Companies to Announce Fourth Quarter and Full Year 2025 Results on February 26, 2026

    DETROIT, Feb. 4, 2026 /PRNewswire/ -- Rocket Companies, Inc. (NYSE:RKT) ("Rocket Companies" or "the Company"), the Detroit-based fintech platform including mortgage, real estate, title and personal finance businesses, today announced that the Company will issue its fourth quarter and full year 2025 earnings on February 26, 2026. Leadership will host a conference call to discuss results at 4:30 p.m. ET on that date. A press release detailing the Company's results will be issued prior to the call. RKT) is a Detroit-based fintech platform company including mortgage, real estate and personal finance businesses: Rocket Mortgage,

    2/4/26 7:00:00 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    CION Investment Corporation Schedules 2025 Fourth Quarter and Year-End Earnings Release and Conference Call

    Call Scheduled for 11:00 a.m. ET on Thursday, March 12, 2026 CION Investment Corporation (NYSE:CION) ("CION") announced today that it will report its financial results for the fourth quarter and year ended December 31, 2025 on Thursday, March 12, 2026, prior to the opening of the financial markets. CION will discuss those results in an earnings conference call at 11:00 a.m. ET that same day. Participant Dial-in Numbers: Domestic (Toll-Free): 877-484-6065 International (Toll): +1 201-689-8846 All participants are asked to dial in approximately 10 minutes before start time. An accompanying slide presentation will be available in PDF format in the Investor Resources section of CION's w

    1/21/26 8:00:00 AM ET
    $CION
    Finance/Investors Services
    Finance

    Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

    ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This compares with net loss attributable to common stockholders of $75.4 million, or $4.06 per basic and diluted share, and no revenue for the prior year.

    12/19/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CION
    $OTLK
    $RKT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at Rocket Companies Inc. on Jun 21

    Recently, there has been a series of insider purchases at Rocket Companies Inc. by Director Rizik Matthew. On 2024-06-21, Director Rizik Matthew made a purchase of $8,648 worth of shares, acquiring 622 units at a price of $13.90. This transaction increased his direct ownership by 0.09% to 706,108 units, as reported in SEC Form 4. This purchase indicates confidence from an insider in the company's prospects. Building up to this latest purchase, Rizik Matthew had also bought shares in the previous month. On 2024-05-31, he acquired $4,375 worth of shares (317 units at $13.80), increasing his direct ownership by 0.05% to 702,497 units. Following this, he made purchases on 2024-06-05, 2024-06-07

    6/22/24 7:57:56 PM ET
    $RKT
    Finance: Consumer Services
    Finance

    Insider Analysis: Purchase at Rocket Companies Inc. on Jun 7

    Rizik Matthew, a prominent figure at Rocket Companies Inc., has been steadily increasing his direct ownership in the company through a series of insider purchases over the past couple of months. The most recent purchase, which took place on June 7, 2024, saw Rizik Matthew acquiring $8,630 worth of shares, equivalent to 602 units at $14.34 per share. This transaction resulted in a marginal increase in his direct ownership by 0.09%, bringing his total direct ownership to 703,727 units as reported in the SEC Form 4. When we examine the pattern of Rizik Matthew's insider purchases leading up to the latest transaction, we can observe a consistent trend of incremental increases in direct ownershi

    6/10/24 12:42:26 AM ET
    $RKT
    Finance: Consumer Services
    Finance

    $CION
    $OTLK
    $RKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

    SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

    11/14/24 4:55:26 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rocket Companies Inc.

    SC 13G/A - Rocket Companies, Inc. (0001805284) (Subject)

    11/14/24 2:20:13 PM ET
    $RKT
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Rocket Companies Inc.

    SC 13G/A - Rocket Companies, Inc. (0001805284) (Subject)

    11/12/24 10:34:15 AM ET
    $RKT
    Finance: Consumer Services
    Finance